German biotech firm Evotec plans to list on the Nasdaq under the symbol "EVO" on November 4th.
The company would look to raise up to $575.5 million in the IPO by offering 22 million American depositary shares (ADSs) at $26.16 each, according to its filing. Each ADS represents one-half of an ordinary share.
According to Reuters, Evotec SE would seek a valuation of about $9.2 billion in its initial public offering in the United States. BofA Securities and Morgan Stanley are the lead underwriters for the offering.
As of October 31st, The company has a market capitalization of $8.2 billion on the Frankfurt Stock Exchange, where its shares are already listed.
Business Overview
Founded in 1993, Hamburg-headquartered Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry.
It offers a suite of technologies that enable faster and cheaper drug discoveries by pharmaceutical companies.
The company last year received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody drugs for the prevention of severe COVID-19.
Evotec's work to date has resulted in 11 disclosed pipeline assets in clinical development, and over 100 pipeline assets in the discovery and preclinical phase.
In the meanwhile, it has developed a broad multi-disciplinary network of collaborations with over 800 partnerships across the pharmaceutical and biotechnology industry and academia.
Evotec generate revenue through three core collaboration routes:
1)“Fee-for-service”: byproviding stand-alone or fully integrated drug discovery and development solutions to partners on a fee-for-service and FTE-rate basis;
2)EVOroyalty: by receiving milestones and royalties on assets;
3)EVOequity: through equity ownership in emerging, highly innovative companies and translational academic institutional projects.
As of June 30, 2021, it had 24 investments with 90 active projects in our EVOequity pipeline.
Financial Performance
Revenues from contracts with customers increased by 17.5%, from €231.0 million for the six months ended June 30, 2020 to €271.3 million in the six months ended June 30, 2021.
The increase is mainly due to a positive performance across all business lines as well as the higher contribution of Just – Evotec Biologics.
Net income increased by €105.5 million from €7.26 million in the six months ended June 30, 2020 to €112.71 million in the six months ended June 30, 2021. The increase is mainly resulted from the fair value adjustment of Evotec’s participation in Exscientia Ltd. in the amount of €116.1 million.
Click to view the prospectus
$Evotec (EVO.US)$

The core concept of investment is to buy stocks to buy companies. To study the relative advantages and competitiveness of companies in the industry. The future development prospects of the industry, etc. The lower-risk investment method is to invest in monopolistic companies in industries that the world cannot change. Coca-Cola, Moutai, luxury brand Hermes, etc. Because the future cash flow discount can be very easy to predict, and the future development of the company can be seen more clearly. The higher risk is to invest in companies that can change the world, such as disruptive technology and new energy. The revolutionary innovation of science and technology creates brand-new industries and replaces traditional industries. You can refer to the invention of gasoline trucks in the past to replace steam engines. The invention of Internet e-commerce impacts the traditional retail industry. The current progress of new energy impacts the traditional gasoline truck industry in the near future. Will be completely replaced in the future. This investment method is similar to the philosophy of Ms. Mu Mu, and the investment philosophy of Sun Zhengyi’s Vision Fund. Excellent investors need to stand on the shoulders of the CEO to see the future development of the company, and sometimes even need A more unique vision. Good company + good industry + time = investment success
$Tesla (TSLA.US)$ $Hermes International SA (HESAY.US)$ $Coca-Cola (KO.US)$ $Kweichow Moutai (600519.SH)$

$Kweichow Moutai (600519.SH)$ h

Elon Musk is the richest person in the world, and he is now worth as much as Bill Gates and Warren Buffett combined! How crazy! His net worth tops $230 billion, which equals around 876000 Ferrari 488s, or 250 million iPhones or 62.5 billion Big Macs!!!
Also, he wants Bezos to know he's No.1. LOL...
Musk has added more than $60 billion to his fortune this year thanks to the strong performance of $Tesla (TSLA.US)$ as well as a recent share sale at SpaceX which valued the company at $100 billion.
He's so successful in managing the company and making investments. I believe he is the best entrepreneur and investor! Even Bill Gates &his $Microsoft (MSFT.US)$ and Buffett &his $Berkshire Hathaway-A (BRK.A.US)$ can't be comparable!
Tell me your favorite CEO and his company if you disagree!
Rewards calling! Comment to win rewards!
Moomoo news team and I hold the event together for a month! I will post discussions every day and Moomoo news team will support the event with reward points! We will pick the top 2 'liked' and top 3 'insightful' comments every weekday& top 10 'liked' and top 10 'insightful' comments every weekend to be the winners.
For more details, click here.
Follow me to join the latest discussion!